IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors
August 04 2021 - 8:00AM
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical
company focused on the discovery and development of innovative
gamma-delta T-cell therapies utilizing its DeltEx platform,
announces the appointments of Emily Fairbairn and Luba Greenwood as
new members of its Board of Directors.
“Emily and Luba have vast experience as entrepreneurs,
executives, board members and investors of companies across
multiple therapeutic areas in the biopharmaceutical industry,” said
Alan S. Roemer, Chairman of IN8bio’s Board of Directors. “We
welcome them both to our Board of Directors and look forward to
their strategic insights and operational guidance as we continue to
advance our clinical-stage gamma-delta T-cell programs in solid and
liquid tumors. Their experience will be invaluable as we execute on
our mission of bringing novel cellular therapies to cancer
patients.”
Ms. Fairbairn is a highly experienced executive and seasoned
investor with decades of experience in financial leadership
positions. She is currently a principal of Transcend Partners and
was co-founder and CEO of Ascend Capital for nearly 20 years, a San
Francisco area based, multi-billion-dollar hedge fund that managed
assets for pensions, endowments, public companies and other
institutional clients. Prior to Ascend, Ms. Fairbairn conducted
equity portfolio construction and financial planning for
high-net-worth clients at Merrill Lynch. She currently serves on
the funding board of the MIT Sandbox Innovation Fund mentoring
aspiring entrepreneurs and is the Chair of the Board at Movano
Inc., a medical technology company developing wearable devices that
measure key health data including blood glucose levels and blood
pressure. She is also a dedicated advocate of funding research for
a realizable diagnostic and cure for Lyme+, which affects ~500,000
patients annually in the United States.
Ms. Greenwood is a veteran executive, investor and company
builder with deep experience across the life sciences, technology
and healthcare sectors. She serves as Managing Partner of Binney
Street Capital LLC, a venture capital fund established by the Dana
Farber Cancer Institute Venture Fund. Ms. Greenwood co-founded and
is currently CEO of LUCA Biologics, Inc., a women's health and
microbiome company. Previously, she was Head of Strategic Business
Development and Corporate Ventures at Google Life Sciences (now
Verily) and Vice President of Global Business Development and
Mergers & Acquisitions at F. Hoffmann-La Roche Ltd. where she
established and led the East Coast Innovation Hub. She serves on
multiple boards, including the Massachusetts Biotechnology Council
(MassBio), Kojin, Brooklyn ImmunoTherapeutics, BenchSci and
Entrinsic Health. She began her career at Wilmer Cutler Pickering
Hale and Dorr as a litigator and regulatory, policy, and
intellectual property expert. Ms. Greenwood is a member of the
Massachusetts bar.
Ms. Fairbairn will be serving on the nomination and corporate
governance committee, while Ms. Greenwood will be serving on the
audit and compensation committees. Their terms will both expire at
the annual meeting of stockholders to be held in 2022.
About IN8bioIN8bio is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of gamma-delta T-cell product candidates for
solid and liquid tumors. Gamma-delta T-cells are a specialized
population of T-cells that possess unique properties, including the
ability to differentiate between healthy and diseased tissue.
IN8bio’s DeltEx platform employs allogeneic, autologous and
genetically modified approaches to develop cell therapies, designed
to effectively identify and eradicate tumor cells.
IN8bio is currently conducting two investigator-initiated Phase
1 clinical trials for its lead gamma-delta T-cell product
candidates: INB-200 for the treatment of newly diagnosed
glioblastoma and INB-100 for the treatment of patients with
leukemia undergoing hematopoietic stem cell transplantation. IN8bio
also has a broad portfolio of preclinical programs focused on
addressing other solid tumor types.
For more information about IN8bio and its programs, please visit
www.IN8bio.com.
Company Contact:IN8bio, Inc.Kate Rochlin,
Ph.D.+1 646.600.6GDT (6438)info@IN8bio.com
Investors:Solebury TroutNicholas Colangelo + 1
646.378.2929ncolangelo@troutgroup.com
Media:Burns McClellan, Inc.Robert Flamm, Ph.D.
/ Harrison Wong212-213-0006 ext. 364 / 316rflamm@burnsmc.com /
hwong@burnsmc.com
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Jul 2023 to Jul 2024